Posted by Michael Wonder on 16 Oct 2025
Incyte Canada announces Health Canada approval of Opzelura (ruxolitinib) cream for the treatment of atopic dermatitis in children ages 2-11
15 October 2025 - First and only topical JAK inhibitor cream approved in Canada for paediatric atopic dermatitis.
Incyte Biosciences Canada today announced that Health Canada has approved Opzelura (ruxolitinib phosphate)) cream 1.5%, a non-steroidal topical Janus Kinase (JAK) inhibitor, for the topical treatment of mild to moderate atopic dermatitis in paediatric patients 2 years of age or older, whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids, topical calcineurin inhibitors) or when those therapies are not advisable.
